ClinicalTrials.gg

Program

RO7821657

A development code.

Its studies are led by Hoffmann-La Roche.

Furthest: phase 1, since Oct 14, 20261 company-led study, 1 open or runningNext primary completion: May 31, 2030 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hoffmann-La Roche11 open or runningphase 1since Oct 14, 2026Oct 14, 2026May 31, 2030phase 1 · NCT07883577

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 14, 2026First study: phase 1 study in Locally Advanced or Metastatic Solid TumorsFirst studyNCT07883577 · 405 planned · Denmark, United Kingdom

Ahead

  1. May 31, 2030Primary completion: phase 1 study in Locally Advanced or Metastatic Solid TumorsNCT07883577

TargetBeta

CEACAM5 →read by rule
“A First In-Human, Multicenter, Phase I Clinical Study of RO7821657, a Protease Activated TCB Antibody That Targets CEACAM5, in Participants With Locally Advanced and/or Metastatic Solid Tumors”study text, by rule · the study

Other programs on CEACAM5

ProgramCompanyFurthest phaseStudies
precemtabart tocentecanruleMerck KGaA, Darmstadt, Germanyphase 34
Anti-CEA/Anti-4-1BB Bispecific Antibody LM-24C5Sino Biopharmaceuticalphase 22
Anti-CEACAM5 Antibody-drug Conjugate BMS-986490ruleBristol-Myers Squibbphase 21
Anti-CEACAM5 Antibody-drug Conjugate IBI3020ruleInnovent Biologicsphase 11
tusamitamab sonditecanPfizerphase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07883577Locally Advanced or Metastatic Solid Tumors · Denmark, United Kingdom1RecruitingMay 31, 2030405

How it is read

Names in the registry

  • “RO7821657”, 1 entry

Codes read as this program: RO7821657.

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.